和元生物技术（上海）股份有限公司 关于完成董事会换届选举及聘任高级管理人员的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上海证券交 易所科创板股票上市规则》（以下简称"《科创板上市规则》"）、《上海证券交 易所科创板上市公司自律监管指引第 1 号——规范运作》等法律、法规、规范性 文件及《和元生物技术（上海）股份有限公司章程》（以下简称"《公司章程》"） 等有关规定，和元生物技术（上海）股份有限公司（以下简称"公司"）于 2025 年 6 月 27 日召开 2025 年第二次临时股东大会，选举产生了公司第四届董事会非 独立董事（不含职工代表董事）和独立董事，并与公司职工代表大会选举产生的 职工代表董事，共同组成公司第四届董事会。 证券代码：688238 证券简称：和元生物 公告编号：2025-048 公司于 2025 年 6 月 27 日召开第四届董事会第一次会议，审议通过了《关于 选举公司第四届董事会董事长的议案》《关于选举公司第四届董事会各专门委员 会 ...

证券代码：688238 证券简称：和元生物 公告编号：2025-O50 和元生物技术（上海）股份有限公司 关于召开2025年第三次临时股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 网络投票起止时间：自2025 年 7 月 16 日 一、 召开会议的基本情况 （一） 股东会类型和届次 2025年第三次临时股东会 召开日期时间：2025 年 7 月 16 日 14 点 00 分 召开地点：上海市浦东新区国际医学园区紫萍路 908 弄 19 号 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 至2025 年 7 月 16 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过互 股东会召开日期：2025年7月16日 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 （二） 股东会召集人：董事会 （三） 投票方式：本次股东会所 ...

和元生物技术（上海）股份有限公司 董事会薪酬与考核委员会关于公司 2025 年限制性股票激励 计划（草案）的核查意见 和元生物技术（上海）股份有限公司（以下简称"公司"）董事会薪酬与考 核委员会参照并依据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华 人民共和国证券法》(以下简称"《证券法》")、《上市公司股权激励管理办法》(以 下简称"《管理办法》")、《上海证券交易所科创板股票上市规则》(以下简称"《科 创板上市规则》")、《科创板上市公司自律监管指南第 4 号——股权激励信息披 露》等相关法律、法规及规范性文件和《和元生物技术（上海）股份有限公司章 程》(以下简称"《公司章程》")的有关规定,对《公司 2025 年限制性股票激励计 划（草案）》(以下简称"《激励计划(草案)》")进行了核查,发表核查意见如下： 1、公司不存在《管理办法》规定的不得实行股权激励的以下情形： （1）最近一个会计年度财务会计报告被注册会计师出具否定意见或者无法 表示意见的审计报告； （2）最近一个会计年度财务报告内部控制被注册会计师出具否定意见或无 法表示意见的审计报告； （3）上市后最近 36 个月内出现过未按法 ...

Core Points - The company is holding its second extraordinary general meeting of shareholders in 2025 to discuss various proposals related to corporate governance and board elections [1][9][11] Meeting Procedures - The company has established guidelines for the meeting to ensure order and efficiency, including identity verification for attendees and a requirement for prior registration [2][4] - Attendees must arrive at least 30 minutes before the meeting to complete registration and present necessary documentation [2][3] - Voting will be conducted through a combination of on-site and online methods, with specific time frames for each [4][6] Agenda Items - The meeting will address several key proposals, including the cancellation of the supervisory board and amendments to the company's articles of association [9][10] - The company plans to elect a new board of directors, with nominations for both non-independent and independent directors [11][13] - The election will utilize a cumulative voting system, allowing shareholders to vote on multiple candidates simultaneously [12][14] Governance Improvements - The company aims to enhance its governance structure in line with recent legal and regulatory changes, including the implementation of new company laws and guidelines [10][11] - Specific internal governance policies are proposed for revision to align with the updated articles of association [10]

股票简称：和元生物 股票代码：688238 2025 年第二次临时股东 大会会议资料 和元生物技术（上海）股份有限公司 OBiO Technology (Shanghai) Corp., Ltd. 2025 年 6 月 和元生物技术（上海）股份有限公司 2025 年第二次临时股东大会会议资料目录 | 2025 年第二次临时股东大会会议须知 | 2 | | --- | --- | | 2025 年第二次临时股东大会会议议程 | 4 | | 2025 年第二次临时股东大会会议议案 | 7 | | 议案一、《关于取消公司监事会并修订<公司章程>的议案》 | 8 | | 议案二、《关于修订公司部分治理制度的议案》 | 9 | | 议案三、《关于公司董事会换届选举暨选举第四届非独立董事（不含职工代表 | | | 董事）的议案》 | 11 | | 议案四、《关于公司董事会换届选举暨选举第四届独立董事的议案》 | 13 | 1 和元生物技术（上海）股份有限公司 2025 年第二次临时股东大会会议资料 和元生物技术（上海）股份有限公司 2025 年第二次临时股东大会会议资料 和元生物技术（上海）股份有限公司 2025 年第二 ...

和元生物技术（上海）股份有限公司（以下简称"公司"）首次公开发行股 票所募集资金已按计划投入使用完毕，公司将专门用于募集资金存储和使用的银 行账户予以注销，并于近日完成了相关银行账户的注销手续，现将具体情况公告 如下： 一、募集资金基本情况 证券代码：688238 证券简称：和元生物 公告编号：2025-044 和元生物技术（上海）股份有限公司 关于募集资金使用完毕并注销募集资金专户的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据中国证券监督管理委员会于 2022 年 1 月 11 日出具的《关于同意和元生 物技术（上海）股份有限公司首次公开发行股票注册的批复》（证监许可〔2022〕 61 号），并经上海证券交易所同意，公司向社会公开发行人民币普通股（A 股） 100,000,000 股，每股面值为人民币 1 元，发行价格为每股人民币 13.23 元，募 集资金总额为人民币 1,323,000,000.00 元，扣除发行费用后实际募集资金净额 为人民币 1,197,464,432.14 元。截至 2022 年 ...

Meeting Information - The shareholder meeting of He Yuan Biotechnology (Shanghai) Co., Ltd. is scheduled for June 27, 2025 [1][3] - The meeting will utilize a combination of on-site and online voting methods [1][3] - Online voting will be conducted through the Shanghai Stock Exchange's shareholder meeting voting system, available from 9:15 AM to 3:00 PM on the meeting day [1][3] Voting Procedures - Shareholders can vote via the trading system or the internet voting platform, with specific time slots for each [5][6] - Shareholders must ensure that their votes do not exceed their entitled voting rights, or those votes will be considered invalid [5] - The first voting result will prevail in case of duplicate votes through different methods [5] Attendance and Registration - Shareholders registered with China Securities Depository and Clearing Corporation Limited as of June 19, 2025, are eligible to attend the meeting [6] - Registration for the meeting will take place on June 20, 2025, at a specified location [8] Proxy Voting - Shareholders may appoint proxies to attend and vote on their behalf, with specific documentation required for the proxy [6][9] - The proxy must present identification and authorization documents to register for the meeting [6][9] Voting Methodology - The meeting will adopt a cumulative voting system for the election of directors and independent directors [9][10] - Each shareholder's voting power is proportional to the number of shares held, allowing for flexible distribution of votes among candidates [10]

Group 1 - The company held its 22nd meeting of the third board of directors on June 10, 2025, with all seven directors present, complying with relevant laws and regulations [1][2] - The board approved the nomination of four candidates for the fourth board of non-independent directors, with a term of three years starting from the approval date by the shareholders' meeting [2][3] - The board also approved the nomination of four candidates for the fourth board of independent directors, with the same term conditions as the non-independent directors [2][3] Group 2 - The company decided to abolish the supervisory board and amend its articles of association to enhance corporate governance, with the supervisory board's powers being transferred to the audit committee of the board [3][4] - The board approved the formulation and revision of several internal governance systems to align with the latest amendments to the articles of association and relevant regulations [4] - A proposal was made to convene the second extraordinary general meeting of shareholders in 2025 on June 27, 2025, which was also approved by the board [4][5]

Core Viewpoint - The company, He Yuan Biotechnology (Shanghai) Co., Ltd., is preparing for an early board of directors election as the current term will expire in September 2025, in accordance with relevant laws and regulations [1][2]. Board Election Summary - The fourth board of directors is proposed to consist of 9 members, including 5 non-independent directors (1 employee representative) and 4 independent directors [1]. - The board has nominated candidates for the fourth board, including Pan Oudong, Yin Shan, Pan Junyi, and Wang Fujie as non-independent directors, and Gao Guolei, Hao Mei, Wu Danfeng, and Hou Xuchao as independent directors [1][2]. - The independent director candidates must be approved by the Shanghai Stock Exchange before being submitted for shareholder meeting review [2]. - The second extraordinary general meeting of shareholders in 2025 will vote on the board election, with cumulative voting for both non-independent and independent directors [2]. Other Information - The current board has been diligent and contributed positively to the company's operations and development [3]. - The candidates for the board have met the qualifications required by relevant laws and regulations, and none are disqualified from serving as directors [2][3].

General Principles - The implementation rules for the cumulative voting system aim to enhance the corporate governance structure of He Yuan Biotechnology (Shanghai) Co., Ltd. and ensure that all shareholders can fully exercise their rights in electing directors, particularly protecting the interests of minority shareholders [2][4] - The cumulative voting system allows shareholders to have voting rights equal to the product of their shares and the total number of directors to be elected, enabling them to concentrate votes on one candidate or distribute them among several candidates [2][6] Nomination of Director Candidates - Non-employee representative director candidates can be nominated by the board or shareholders holding more than 1% of shares for over 90 days, with a limit on the number of candidates nominated [4][5] - Employee representative director candidates are elected through democratic processes by company employees [4][5] Voting Principles - Each shareholder's voting rights during the election of directors are calculated based on their shareholding and the number of directors to be elected [6][7] - Shareholders can choose to concentrate their votes on specific candidates or distribute them among all candidates, but cannot exceed the number of candidates to be elected [6][7] Election of Directors - Directors are elected based on the total votes received, with a requirement that the votes must exceed half of the total voting rights held by attending shareholders [9][10] - In cases of tied votes among candidates, specific procedures are outlined for resolving the tie and ensuring that the board remains compliant with legal requirements [9][10] Special Procedures for Cumulative Voting - The company must clearly state the use of the cumulative voting system in the notice for the shareholders' meeting and provide detailed voting instructions [11][12] - Shareholders can vote in person or authorize others to vote on their behalf, and online voting systems may also be utilized [11][12]